Research
Continually investing
in our pipeline
As times change, so do your treatment needs. Ortho Dermatologics wants to help you help your patients now and in the future.
Watch
Radhakrishnan (RK) Pillai, PhD Vice President,
Research and Development Ortho Dermatologics
Jonathan S. Weiss, MD, in practice in Georgia for 33 years
Investing in the Future
Join Radhakrishhnan (RK) Pillai, PhD,Ortho Dermatologics' Head of
Dermatology Development, and
Dr. Jonathan Weiss, MD,
dermatologist and assistant
clinical professor, as they discuss
everything from formulation
to finished product
DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
Approval Available
ALTRENO® (tretinoin) Lotion, 0.05%
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
Approval Available
ARAZLO™ (tazarotene) Lotion, 0.045%
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
Approval Available
BRYHALI® (halobetasol propionate) Lotion, 0.01%
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
Approval Available
CABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
Approval Available